Therapeutic drug monitoring of cyclosporine and TACROLIMUS (cas 109581-93-3) in Myanmar kidney transplant patients
-
Add time:07/23/2019 Source:sciencedirect.com
IntroductionRenal transplantation is one of the best options for patients suffering from end stage renal disease (ESRD). Cyclosporine and TACROLIMUS (cas 109581-93-3) are mainly applied in immunosuppressive therapy after transplantation of liver, kidney, heart, and other organs. The used of immunosuppressant drugs improve the survival of transplanted organs and reduce organ rejection. Because of their narrow therapeutic index and significant inter-individual variability in blood concentrations, they need to monitor carefully. Therapeutic drug monitoring of tacrolimus and cyclosporine were needed to optimize the outcome in patients after renal transplantations. Maintaining the drugs levels reduce the risks of toxicity or rejection, respectively.
We also recommend Trading Suppliers and Manufacturers of TACROLIMUS (cas 109581-93-3). Pls Click Website Link as below: cas 109581-93-3 suppliers
Prev:TACROLIMUS (cas 109581-93-3) ointment in the management of atopic keratoconjunctivitis
Next:A sample processing method for immunoassay of whole blood TACROLIMUS (cas 109581-93-3)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Comparison of anti-atopic dermatitis activities between DHMEQ and TACROLIMUS (cas 109581-93-3) ointments in mouse model without stratum corneum07/31/2019
- An open-label, randomized trial indicates that everolimus with TACROLIMUS (cas 109581-93-3) or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients07/30/2019
- Relationships between concomitant biologic DMARDs and prednisolone administration and blood TACROLIMUS (cas 109581-93-3) exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients07/29/2019
- Recipient ABCB1, donor and recipient CYP3A5 genotypes influence TACROLIMUS (cas 109581-93-3) pharmacokinetics in liver transplant cases07/28/2019
- Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells07/27/2019
- Effectiveness and safety of TACROLIMUS (cas 109581-93-3) therapy for myasthenia gravis: A single arm meta-analysis07/26/2019
- Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study07/25/2019
- A sample processing method for immunoassay of whole blood TACROLIMUS (cas 109581-93-3)07/24/2019
- TACROLIMUS (cas 109581-93-3) ointment in the management of atopic keratoconjunctivitis07/22/2019